威尼斯人
启动(农业)
生物
癌症研究
夏普
小发夹RNA
醛类白血病
细胞凋亡
药理学
T细胞
医学
基因敲除
免疫学
免疫系统
半胱氨酸蛋白酶
白血病
程序性细胞死亡
生物化学
慢性淋巴细胞白血病
植物
发芽
作者
Yang Li,Xin He,Lei Zhang,Haojie Dong,Xin Wang,Yuan Che,Umesh Prasad Yadav,Meng Liu,Lianjun Zhang,Shuai‐Shuai Ge,Guohua Wu,Yu-Hsuan Fu,Wei Chen,Ya-Huei Kuo,Liang Chen,Guido Marcucci,Shaoyuan Wang,Ling Li
出处
期刊:Blood
[Elsevier BV]
日期:2024-11-05
卷期号:144 (10): 1328-1343
标识
DOI:10.1182/blood.2026034144
摘要
Abstract Arginine methylation catalyzed by protein arginine methyltransferases (PRMTs) is required for cancer cell proliferation, but whether PRMTs mediate resistance to therapy remains unclear. Here, we performed loss-of-function screens in venetoclax-resistant (VEN-R) acute myeloid leukemia (AML) patient-derived xenograft cells and found that PRMT9 plays a critical role in promoting VEN resistance. Specifically, VEN-R AML samples exhibited high levels of PRMT9, and PRMT9 inhibition resensitized AML cells to VEN treatment. In preclinical resistant models, genetic ablation of PRMT9 synergized with VEN to eradicate AML cells. Consistently, pharmacologic inhibition of PRMT9 combined with VEN produced similar effects in VEN-R AML mouse models. Mechanistically, PRMT9 ablation disrupted RNA splicing by inducing exon skipping in mRNA encoding ALG13, an uridine diphosphate (UDP)-N-acetylglucosaminyltransferase subunit, thereby downregulating expression of the VEN efflux transporter encoded by the adenosine triphosphate–binding cassette subfamily C member 1 gene. PRMT9 inhibition also suppressed protein synthesis, leading to downregulation of short-lived oncoproteins such as MCL1. These findings establish a connection between PRMT9-mediated arginine methylation and poor VEN responsiveness and demonstrate that targeting PRMT9 may represent a viable strategy to overcome VEN resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI